NeoGenomics, Inc.
NEODiagnostics & Research
$17.38−3.07%As of Oct 30vs prior close
- Market cap
- $2.2B
- From 52W high
- −12.71%
- Revenue (LTM)
- $787.8M
- Net margin
- -4.10%
- Dividend yield
- 0.00%
Nomior Score
61
Ascendant MoverSpeculativeTop 24% of the scored universe
Growth74
Quality44
Value43
Momentum85
Resilience41
Growth
+13.55%revenue a year over 9 fiscal years
YE16 $231.8MLTM $787.8M
Connections
Revenue to profitQ3 YE26
The operating loss was 4% of revenue, narrower by 11 pts on a year.
Latest resultsthird quarter of 2026
- Net loss
- $8 million
Sales grew in the quarter, led by strong growth in clinical revenue and next-generation sequencing testing. The company still reported a net loss, which narrowed sharply from the prior year, while adjusted EBITDA improved. Management raised its full-year revenue and adjusted EBITDA guidance and announced a planned CEO succession.
Who owns it
2funds